免疫检查点PD1/PDL1,TIM3/GAL9和关键免疫媒介的景观揭示了慢性髓性白血病中imatinib反应的差异性表达动态
María Jazmín Toloza1, Marco Lincango1, María Fernanda Camacho1
1Laboratorio de Genética Hematológica, Instituto de Medicina Experimental, IMEX-CONICET/ Academia Nacional de Medicina, Pacheco de Melo 3081, Ciudad Autónoma de Buenos Aires, C1425AUM, Argentina.
Annals of hematology
|November 6, 2024
概括
慢性骨髓性白血病 (CML) 患者表现出免疫系统受损,这些免疫系统在用氨酸激酶抑制剂治疗后得到改善. 这项研究追踪了Imatinib治疗CML患者的免疫基因表达,揭示了与治疗反应相关的关键变化.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 慢性髓性白血病 (CML) 的特点是免疫系统受损,影响抗瘤反应.
- 在CML患者中,最大限度的免疫恢复与用氨酸激酶抑制剂 (TKI) 实现的深度分子反应有关.
研究的目的:
- 研究CML患者在第一年伊马替尼治疗期间的19个关键免疫媒介的动态表达模式.
- 为了将免疫基因表达特征与治疗反应和CML中的分子结果相关联.
主要方法:
- 对来自89名CML患者和52名健康捐赠者的171个外周血液样本中的19个免疫媒介的基因表达分析.
- 在一年的时间内对43名CML患者进行长度监测,他们接受伊马替尼治疗.
- 单变体,无监督和多变体分析以评估基因表达动态和治疗反应.
主要成果:
- 大多数免疫媒介最初在CML患者中减弱,但TNF,ARG1和IL4.4等例外存在.
- 免疫媒介水平在治疗期间通常正常化,TNF和IL6在3个月后暂时增加,特别是在最佳反应者中.
- 在12个月内,非最佳响应者显示ARG1升高,并从PD1/PDL1转向TIM3/GAL9免疫检查点主导地位.
结论:
- 在接受伊马替尼布治疗的CML患者中,纵向免疫基因表达概况提供了对免疫恢复动态的见解.
- 免疫媒介表达模式,特别是ARG1和免疫检查点,可以在CML中区分最佳和非最佳治疗反应.
- 了解这些免疫动态可以为治疗策略提供信息,并改善CML患者的治疗结果.
更多相关视频
相关概念视频
Cytotoxic T Cells-mediated Immune Response
849
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


